Hepatoprotective efficacy of ursodeoxycholic acid in pediatrics acute lymphoblastic leukemia

Pediatric Hematology and Oncology

Volumn 29, Issue 7, 2012, Pages 627-632

  Mohammed Saif, Mojeb ^a   Farid, Samar F ^a   Khaleel, Sahar A ^b   Sabry, Nirmeen A ^a   El Sayed, Manal H ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Acute lymphoblastic leukemia; Chemotherapy; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; UREA; URSODEOXYCHOLIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; LIVER PROTECTION; LIVER TOXICITY; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UREA BLOOD LEVEL;

ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FOLLOW-UP STUDIES; HUMANS; LIVER; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; PROTECTIVE AGENTS; URSODEOXYCHOLIC ACID;

EID: 84866906161     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2012.713083     Document Type: Article

References (25)

1. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist. 2001;6(2):162-176.
2. Topley J, Benson J, Squier M, Chessells J. Hepatotoxicity in the treatment of acute lymphoblastic leukaemia. Med Pediatr Oncol. 1979;7(4):393-399.
3. McIntosh S, Davidson DL, O'Brien RT, Pearson HA. Methotrexate hepatotoxicity in children with leukemia. J Pediatr. 1977;90(6):1019-1021.
4. Kamen B, Nylen P, Camitta B, Bertino J.Methotrexate accumulation and folate depletion in cells as a possiblemechanism of chronic toxicity to the drug. Br J Haematol. 1981;49(3):355-360.
5. Ruymann FB, Mosijczuk AD, Sayers RJ. Hepatoma in a child with methotrexate-induced hepatic fibrosis. JAMA. 1977;238(24):2631-2633.
6. Farrow AC, Buchanan GR, Zwiener RJ, et al. Serumaminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 1997;15(4):1560-1566.
7. Hagey LR, Crombie DL, Espinosa E, et al. Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores. J Lipid Res. 1993;34(11):1911-1917.
8. Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med. 2007;357(15):1524-1529.
9. Buscher HP,ZietzschmannY,GerokW.Positive responses tomethotrexate andursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. J Hepatol. 1993;18(1):9-14.
10. PerryMC.TheChemotherapySourceBook. 4th ed. Philadelphia: LippincottWilliams&Wilkins; 2008.
11. Lim A, Jazrawi R, Northfield T. The ursodeoxycholic acid story in primary biliary cirrhosis. Gut. 1995;37(3):301-304.
12. Benz C, Angermuller S, Otto G, et al. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes. Eur J Clin Invest. 2000;30(3):203-209.
13. Hofmann AF. Bile acids: the good, the bad, and the ugly. Physiology. 1999;14(1):24-29.
14. Lapenna D, Ciofani G, Festi D, et al. Antioxidant properties of ursodeoxycholic acid. Biochem Pharmacol. 2002;64(11):1661-1667.
15. Yoshikawa M, Tsujii T, Matsumura K, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology. 1992;16(2):358-364.
16. Kobayashi K, Terada C, Tsukamoto I. Methotrexate-induced apoptosis in hepatocytes after partial hepatectomy. Eur J Clin Pharmacol. 2002;438(1-2):19-24.
17. Amaral JD, Castro RE, SóA;a S, et al. P53 is a keymolecular target of ursodeoxycholic acid in regulating apoptosis. J Biol Chem. 2007;282(47):34250-34259.
18. Uraz S, Tahan V, Aygun C, et al. Role of ursodeoxycholic acid in prevention ofmethotrexate-induced liver toxicity. Dig Dis Sci. 2008;53(4):1071-1077.
19. Ljubuncic P, Tanne Z, Bomzon A. Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease. Dig Dis Sci. 2000;45(10):1921-1928.
20. Dickinson AM, Proctor S, Jacobs E, et al. Natural killer cell activity in childhood acute lymphoblastic leukaemia in remission. Br J Haematol. 1985;59(1):45-53.
21. Nishigaki Y, Ohnishi H, Moriwaki H, Muto Y. Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E 2 production in primary biliary cirrhosis. Dig Dis Sci. 1996;41(7):1487-1493.
22. Hollingshead L, Faulds D. Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 1991;42(4):690-719.
23. Winick N, Shuster JJ, Bowman WP, et al. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. J Clin Oncol. 1996;14(10):2803-2811.
24. Bessho F, Kinumaki H, Yokota S, et al. Liver function studies in children with acute lymphocytic leukemia after cessation of therapy. Med Pediatr Oncol. 1994;23(2):111-115.
25. Taqweem MA, Ali Z, Takreem A, Rahman MU. Methotrexate induced hepatotoxicity in patients of rheumatoid arthritis. Development. 2011;3:387-391.